Propanc Biopharma Receives Certificate for "Proenzyme Composition" Patent

Propanc Biopharma has received a certificate of grant for its "proenzyme composition" patent from the US Patent & Trademark Office. The patent covers a future clinical dose of the company's lead asset, PRP, and is part of its intellectual property portfolio consisting of 90 patents filed in major jurisdictions. The portfolio targets the global metastatic cancer treatment market, projected to be worth $111.2 billion by 2027.